Drug Trial Radar · NCT03372057
A Study of Duvelisib in Participants With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Last checked: Nov 19, 2026Latest source record: Mar 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
156
Actual
Start
Feb 22, 2018
Primary completion
Dec 22, 2023
Study completion Dec 22, 2023
Sponsor
- Lead sponsor
- SecuraBioIndustry
- Sponsor type
- Industry
- First posted
- Dec 13, 2017
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, parallel cohort, open-label, Phase 2 study of duvelisib, an oral dual inhibitor of phosphoinositide-3-kinase-delta, gamma (PI3K-δ,γ), in participants with relapsed/refractory peripheral T-cell lymphoma (PTCL).
Conditions
- Peripheral T-cell Lymphoma
Interventions
DuvelisibDrug
Duvelisib PO 25 mg BID or 50 mg BID or 75 mg BID in 28-day cycles.
DuvelisibDrug
Duvelisib PO 75 mg BID in 28-day cycles.
DuvelisibDrug
Duvelisib PO BID in 28-day cycles (dose determined in Optimization Phase).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR) as Assessed by the Investigator Using the Lugano CriteriaTime frame: 56 days (2 cycles; 28-day cycles)
- ORR as Assessed by the Independent Review Committee (IRC) Using the Lugano CriteriaTime frame: 56 days (2 cycles; 28-day cycles)
Locations
36 sites in 5 countries. Site status is shown where the registry gives one.
City of Hope National Medical Center
Duarte, California
University of California - Irvine
Irvine, California
University of California - Los Angeles
Los Angeles, California
Emory University Winship Cancer Institute
Atlanta, Georgia
Northwestern University - Feinberg School of Medicine
Chicago, Illinois
Norton Cancer Institute
Louisville, Kentucky
University of Maryland
Baltimore, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Washington University
St Louis, Missouri
Memorial Sloan Kettering Cancer Center
New York, New York
University of Rochester
Rochester, New York
Stony Brook Cancer Center
Stony Brook, New York
Levine Cancer Institute
Charlotte, North Carolina
Novant Health
Charlotte, North Carolina
Duke University
Durham, North Carolina
The Ohio State University
Columbia, Ohio
Toledo Cancer Center
Toledo, Ohio
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania
Baylor Research Institute - Charles Sammons Cancer Center
Dallas, Texas
Universitätsklinikum Carl Gustav Carus
Dresden, Saxony, Germany
Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV
Halle, Saxony-Anhalt, Germany
ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo
Bergamo, Italy
A.O.di Bologna Policl.S.Orsola
Bologna, Italy
Ieo, Irccs
Milan, Italy
Policlinico Universitario Agostino Gemelli, Università Cattolica del Sacro Cuore
Roma, Italy
Azienda Ospedaliera Santa Maria di Terni
Terni, Italy
Japanese Site 8
Fukuoka, Japan
Japanese Site 5
Kobe, Japan
Japanese Site 3
Miyagi, Japan
Japanese Site 6
Nagoya, Japan
Japanese Site 7
Niigata, Japan
Japanese Site 1
Okayama, Japan
Japanese Site 2
Tokyo, Japan
Japanese Site 4
Tokyo, Japan
Christie Hospital NHS Foundation Trust
Manchester, United Kingdom
Nottingham University Hospitals NHS Trust
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.